A double-blind, placebo-controlled, single-dose, parallel-group study to evaluate the safety and tolerability, the pharmacokinetics (pk), and pharmacodynamics of atacicept after single subcutaneous doses, in healthy japanese and caucasian subjects.

Trial Profile

A double-blind, placebo-controlled, single-dose, parallel-group study to evaluate the safety and tolerability, the pharmacokinetics (pk), and pharmacodynamics of atacicept after single subcutaneous doses, in healthy japanese and caucasian subjects.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2015

At a glance

  • Drugs Atacicept (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2015 New trial record
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top